nach oben

Clinical Research in Cardiology

Erschienen in:

01.10.2013 | Critical Perspective

Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection

verfasst von: Rui Providência, Sérgio Barra, Luís Paiva

Erschienen in: Clinical Research in Cardiology | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Cardiac troponin is widely used for the diagnosis of acute myocardial infarction. In addition to this indication, the elevation of troponin has been found to play a prognostic role in ischemic stroke. It is hypothesized that approximately 15–20 % of all ischemic strokes are associated with atrial fibrillation and that these events are more often fatal. Recent studies have demonstrated that troponin elevation can also be used as a prognosticator in patients with atrial fibrillation and for risk stratification to predict which patients are more prone to stroke or other thromboembolic events. Therefore, troponin appears to play a pivotal role in the overlap of atrial fibrillation and ischemic stroke and the subsequent development of an adverse outcome. The different aspects of this association will be addressed and novel explanations will be proposed to better clarify the underlying mechanisms.

Twerenbold R, Jaffe A, Reichlin T, Reiter M, Mueller C (2012) High-sensitive troponin T measurements: what do we gain and what are the challenges? Eur Heart J 33(5):579–586PubMedCrossRef

Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36(6):1115–1119PubMedCrossRef

Wu AHB, Feng YJ (1998) Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes. Eur Heart J 19(suppl N):N25–N29PubMed

Maynard SJ, Menown IB, Adgey AA (2000) Troponin T or troponin I as cardiac markers in ischaemic heart disease. Heart 83(4):371–373PubMedCrossRef

Jaffe AS (2012) Troponin—past, present, and future. Curr Probl Cardiol 37(6):209–228PubMedCrossRef

Thygesen K, Alpert JS, White HD (2007) Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction Eur Heart J 28:2525–2538

Lavy S, Stern S, Herishianu Y, Carmon A (1968) Electrocardiographic changes in ischemic stroke. J Neur Sci 7:409–415CrossRef

Goldstein DS (1979) The electrocardiogram in stroke: relationship to pathophysiological type and comparison with prior tracings. Stroke 10(3):253–259PubMedCrossRef

Norris JW, Hachinski VC, Myers MG, Callow J, Wong T, Moore RW (1979) Serum cardiac enzymes in stroke. Stroke 10(5):548–553PubMedCrossRef

10.

James P, Ellis CJ, Whitlock RM, McNeil AR, Henley J, Anderson NE (2000) Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ 320:1502–1504PubMedCrossRef

11.

Dixit S, Castle M, Velu RP, Swisher L, Hodge C, Jaffe AS (2000) Cardiac involvement in patients with acute neurologic disease: confirmation with cardiac troponin I. Arch Intern Med 160(20):3153–3158PubMedCrossRef

12.

Etgen T, Baum H, Sander K, Sander D (2005) Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke 36(2):270–275PubMedCrossRef

13.

Di Angelantonio E, Fiorelli M, Toni D, Sacchetti ML, Lorenzano S, Falcou A, Ciarla MV, Suppa M, Bonanni L, Bertazzoni G, Aguglia F, Argentino C et al (2005) Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 76(1):76–81PubMedCrossRef

14.

Scheitz JF, Mochmann HC, Nolte CH, Haeusler KG, Audebert HJ, Heuschmann PU, Laufs U, Witzenbichler B, Schultheiss HP, Endres M (2011) Troponin elevation in acute ischemic stroke (TRELAS)–protocol of a prospective observational trial. BMC Neurol 11:98PubMedCrossRef

15.

Kerr G, Ray G, Wu O, Stott DJ, Langhorne P (2009) Elevated troponin after stroke: a systematic review. Cerebrovasc Dis 28(3):220–226PubMedCrossRef

16.

Myers MG, Norris JW, Hachinski VC, Sole MJ (1981) Plasma norepinephrine in stroke. Stroke 12:200–204PubMedCrossRef

17.

Barber M, Morton JJ, Macfarlane PW, Barlow N, Roditi G, Stott DJ (2007) Elevated troponin levels are associated with sympathoadrenal activation in acute ischaemic stroke. Cerebrovasc Dis 23(4):260–266PubMedCrossRef

18.

Oppenheimer S (1992) The insular cortex and the pathophysiology of stroke-induced cardiac changes. Can J Neurol Sci 19:208–211PubMed

19.

Tatschl C, Stollberger C, Matz K, Yilmaz N, Eckhardt R, Nowotny M, Dachenhausen A, Brainin M (2006) Insular involvement is associated with QT prolongation: eCG abnormalities in patients with acute stroke. Cerebrovasc Dis 21:47–53PubMedCrossRef

20.

Kolin A, Brezina A, Lewis AJ, Norris JW (1989) Quantitative evaluation of myocardial injury induced by acute cerebral ischaemia and its prevention by beta 1-adrenergic blockade. An ultrastructural morphometry study. Br J Exp Pathol 70(6):659–667PubMed

21.

Bugnicourt JM, Rogez V, Guillaumont MP, Rogez JC, Canaple S, Godefroy O (2010) Troponin levels help predict new-onset atrial fibrillation in ischaemic stroke patients: a retrospective study. Eur Neurol 63(1):24–28PubMedCrossRef

22.

Tanindi A, Cemri M (2011) Troponin elevation in conditions other than acute coronary syndromes. Vasc Health Risk Manag. 7:597–603PubMedCrossRef

23.

Norris JW, Kolin A, Hachinski VC (1980) Focal myocardial lesions in stroke. Stroke 11:130

24.

Kolin A, Norris JW (1984) Myocardial damage from acute cerebral lesions. Stroke 15(6):990–993PubMedCrossRef

25.

Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D (2001) Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 32(2):392–398PubMedCrossRef

26.

Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino RB (1996) Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27:1760–1764PubMedCrossRef

27.

Beaulieu-Boire I, Leblanc N, Berger L, Boulanger JM (2012) Troponin elevation predicts atrial fibrillation in patients with stroke or transient ischemic attack. J Stroke Cerebrovasc Dis [Epub ahead of print]

28.

Abboud H, Berror S, Labreuch J, Orjuela K, Amarenco P (2006) GENIC investigators Insular involvement in brain infarction increases risk for cardiac arrhythmia and death. Ann Neurol 59(4):691–699PubMedCrossRef

29.

Oppenheimr S (2006) Cerebrogenic cardiac arrhythmias: cortical lateralization and clinical significance. Clin Auton Res 16:6–11CrossRef

30.

DiPasquale G, Pinelli G, Andreoli A (1987) Holter detection of cardiac arrhythmias in intracranial subarachnoid hemorrhage. Am J Cardiol 59:596–600CrossRef

31.

Bybee KA, Prasad A (2008) Stress-related cardiomyopathy syndromes. Circulation 118(4):397–409PubMedCrossRef

32.

van den Bos EJ, Constantinescu AA, van Domburg RT, Akin S, Jordaens LJ, Kofflard MJ (2011) Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. Eur Heart J 32(5):611–617PubMedCrossRef

33.

Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22):2864–2870PubMedCrossRef

34.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 137(2):263–272PubMedCrossRef

35.

Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE, ATRIA Study Group (2008) Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 51(8):810–815PubMedCrossRef

36.

Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY (2011) A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 9(1):39–48PubMedCrossRef

37.

Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342:d124PubMedCrossRef

38.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151PubMedCrossRef

39.

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125(13):1605–1616PubMedCrossRef

40.

Roldán V, Marín F, Díaz J, Gallego P, Jover E, Romera M, Manzano-Fernández S, Casas T, Valdés M, Vicente V, Lip GY (2012) High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 10(8):1500–1507PubMedCrossRef

41.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992PubMedCrossRef

42.

Wallentin L, Hijazi Z, Siegbahn A, Schollin M, Alexander JH, Atar D, Bernard, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJV, Granger CB. on behalf of the ARISTOTLE Investigators (2012) High sensitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin. Eur Heart J 33(Abstract Supplement, 53)

43.

Zusman O, Amit G, Gilutz H, Zahger D (2012) The significance of new onset atrial fibrillation complicating acute myocardial infarction. Clin Res Cardiol. 101(1):17–22PubMedCrossRef

44.

Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG (1998) Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators. J Am Coll Cardiol 31:1622–1626PubMedCrossRef

45.

Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF (1994) Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol 24:755–762PubMedCrossRef

46.

The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography (1998) Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 128:639–647CrossRef

47.

Bernhardt P, Schmidt H, Hammerstingl C, Lüderitz B, Omran H (2005) Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol 45(11):1807–1812PubMedCrossRef

48.

Bernhardt P, Schmidt H, Sommer T, Lüderitz B, Omran H (2006) Atrial fibrillation—patients at high risk for cerebral embolism. Clin Res Cardiol 95(3):148–153PubMedCrossRef

49.

Bernhardt P, Schmidt H, Hammerstingl C, Lüderitz B, Omran H (2006) Atrial thrombi-a prospective follow-up study over 3 years with transesophageal echocardiography and cranial magnetic resonance imaging. Echocardiography 23(5):388–394PubMedCrossRef

50.

Providência R, Paiva L, Faustino A, Botelho A, Trigo J, Casalta-Lopes J, Nascimento J, Leitão-Marques AM (2012) Cardiac troponin I: Prothrombotic risk marker in non-valvular atrial fibrillation. Int J Cardiol [Epub ahead of print]

51.

Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EH, Lopes ED, McMurray JJV, Granger CB (2012) NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin. Eur Heart J 33.(Abstract Supplement, 51)

52.

Eikelboom J, Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L, Siegbahn A (2010) D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation—a RELY Sub-study. Circulation 122:A18321

53.

Christersson C, Schollin M, Alexander JH, Bersh BJ, Horowitz J, Hylek EM, Mohan P, Granger CB, Wallentin L, Siegbahn A (2012) Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death. Eur Heart J 33 (Abstract Supplement, 51, Abstract session 5297

54.

Aulin JK, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, Siegbahn A, Wallentin L, Yusuf S, Oldgren J (2011) Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. J Am Coll Cardiol 57:E91CrossRef

55.

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM, ROCKETAF Steering Committee Investigators (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127(2):224–232PubMedCrossRef

56.

Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33:2821–2830PubMedCrossRef

57.

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor xA next GEneration in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160:635–641PubMedCrossRef

58.

Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM, Folsom AR (2012) Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol 155(2):217–222PubMedCrossRef

59.

Ehrlich JR, Kaluzny M, Baumann S, Lehmann R, Hohnloser SH (2011) Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol 100(11):1029–1036PubMedCrossRef

60.

Turfan M, Erdogan E, Ertas G, Duran M, Murat SN, Celik E, Baydar C, Tasal A, Vatankulu MA, Sevgili E, Kul S, Yoldas T, Goktekin O (2013) Usefulness of mean platelet volume for predicting stroke risk in atrial fibrillation patients. Blood Coagul Fibrinolysis 24(1):55–58PubMedCrossRef

61.

Gu YL, Voors AA, Zijlstra F, Hillege HL, Struck J, Masson S, Vago T, Anker SD, van den Heuvel AF, van Veldhuisen DJ, de Smet BJ (2011) Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol 100(12):1069–1076PubMedCrossRef

62.

Kurz K, Giannitsis E, Becker M, Hess G, Zdunek D, Katus HA (2011) Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol 100(3):209–215PubMedCrossRef

63.

Volz HC, Laohachewin D, Schellberg D, Wienbrandt AR, Nelles M, Zugck C, Kaya Z, Katus HA, Andrassy M (2012) HMGB1 is an independent predictor of death and heart transplantation in heart failure. Clin Res Cardiol 101(6):427–435PubMedCrossRef

64.

Wasmer K, Köbe J, Dechering D, Milberg P, Pott C, Vogler J, Stypmann J, Waltenberger J, Mönnig G, Breithardt G, Eckardt L (2013) CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. Clin Res Cardiol 102(2):139–144PubMedCrossRef

65.

Ederhy S, Di Angelantonio E, Dufaitre G, Meuleman C, Masliah J, Boyer-Chatenet L, Boccara F, Cohen A (2012) C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillation. Int J Cardiol 159(1):40–46

66.

Ammash N, Konik EA, McBane RD, Chen D, Tange JI, Grill DE, Herges RM, McLeod TG, Friedman PA, Wysokinski WE (2011) Left atrial blood stasis and von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation. Arterioscler Thromb Vasc Biol 31(11):2760–2766PubMedCrossRef

67.

Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H, Hasegawa D, Matsuda O (2007) Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 28(18):2217–2222PubMedCrossRef

68.

Shimizu H, Murakami Y, Inoue S, Ohta Y, Nakamura K, Katoh H, Sakne T, Takahashi N, Ohata S, Sugamori T, Ishibashi Y, Shimada T (2002) High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke 33(4):1005–1010PubMedCrossRef

69.

Providência R, Fernandes A, Paiva L, Faustino A, Barra S, Botelho A, Trigo J, Nascimento J, Leitão-Marques A (2013) Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. Cardiology. 124(1):3–10PubMedCrossRef

70.

Osranek M, Bursi F, Bailey KR, Grossardt BR, Brown RD Jr, Kopecky SL, Tsang TS, Seward JB (2005) Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. Eur Heart J 26(23):2556–2561PubMedCrossRef

Titel: Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection
verfasst von: Rui Providência
Sérgio Barra
Luís Paiva
Publikationsdatum: 01.10.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 10/2013
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0591-0

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2013

Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors

Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes

Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF Study

Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction